Drug Profile
Pioglitazone companion diagnostic - Takeda/Zinfandel
Alternative Names: AD4833/TOMM40Latest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator Takeda; Zinfandel Pharmaceuticals
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 16 May 2018 Takeda terminates a phase III trial for Alzheimer's disease (Diagnosis) in USA, Australia, Switzerland and United Kingdom due to lack of efficacy of the drug (PO) (NCT02284906)
- 25 Jan 2018 Takeda terminates a phase III trial based on a planned interim futility analysis in Alzheimer's disease (Diagnosis) in United Kingdom, USA, Australia, Germany, Switzerland and Italy (PO) (NCT01931566)
- 06 Sep 2017 Phase III development is ongoing for Alzheimer's disease (Diagnosis) in USA, Australia and United Kingdom (NCT02284906)